0.8853
price down icon4.84%   -0.045
after-market Dopo l'orario di chiusura: .89 0.0047 +0.53%
loading
Precedente Chiudi:
$0.9303
Aprire:
$0.91
Volume 24 ore:
338.17K
Relative Volume:
0.37
Capitalizzazione di mercato:
$117.12M
Reddito:
$3.25M
Utile/perdita netta:
$-116.80M
Rapporto P/E:
-0.2903
EPS:
-3.05
Flusso di cassa netto:
$-98.17M
1 W Prestazione:
-28.02%
1M Prestazione:
-2.28%
6M Prestazione:
-29.74%
1 anno Prestazione:
-78.14%
Intervallo 1D:
Value
$0.8603
$0.91
Intervallo di 1 settimana:
Value
$0.8603
$1.27
Portata 52W:
Value
$0.7082
$4.60

Rapt Therapeutics Inc Stock (RAPT) Company Profile

Name
Nome
Rapt Therapeutics Inc
Name
Telefono
(650) 489-9000
Name
Indirizzo
561 ECCLES AVENUE, SOUTH SAN FRANCISCO, CA
Name
Dipendente
67
Name
Cinguettio
Name
Prossima data di guadagno
2024-11-11
Name
Ultimi documenti SEC
Name
RAPT's Discussions on Twitter

Confronta RAPT con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
RAPT
Rapt Therapeutics Inc
0.8853 162.72M 3.25M -116.80M -98.17M -3.05
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 26.10B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
442.05 111.96B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 42.96M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.20 6.39B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
490.28 63.52B 14.09B 4.50B 2.96B 39.28

Rapt Therapeutics Inc Stock (RAPT) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-05-22 Ripresa H.C. Wainwright Buy
2024-12-26 Aggiornamento H.C. Wainwright Neutral → Buy
2024-11-13 Downgrade Stifel Buy → Hold
2024-11-11 Downgrade JP Morgan Neutral → Underweight
2024-11-11 Downgrade Piper Sandler Overweight → Neutral
2024-05-14 Downgrade Wolfe Research Outperform → Peer Perform
2024-05-10 Downgrade Barclays Overweight → Equal Weight
2024-05-10 Downgrade Guggenheim Buy → Neutral
2024-02-22 Downgrade UBS Buy → Neutral
2024-02-21 Downgrade H.C. Wainwright Buy → Neutral
2024-02-21 Downgrade JP Morgan Overweight → Neutral
2024-02-21 Downgrade Leerink Partners Outperform → Market Perform
2024-02-20 Downgrade Cantor Fitzgerald Overweight → Neutral
2024-02-16 Iniziato Evercore ISI Outperform
2024-02-15 Iniziato Wolfe Research Outperform
2023-09-14 Iniziato Berenberg Buy
2023-08-09 Iniziato Stifel Buy
2023-06-15 Iniziato Barclays Overweight
2023-01-04 Iniziato Guggenheim Buy
2022-12-01 Iniziato Goldman Buy
2022-09-21 Iniziato CapitalOne Overweight
2022-05-24 Ripresa Cantor Fitzgerald Overweight
2021-12-09 Iniziato JP Morgan Overweight
2021-08-12 Iniziato SVB Leerink Outperform
2021-06-21 Iniziato Piper Sandler Overweight
2020-06-01 Iniziato H.C. Wainwright Buy
2020-05-19 Iniziato Cantor Fitzgerald Overweight
2020-04-13 Iniziato ROTH Capital Buy
2019-11-25 Iniziato BMO Capital Markets Outperform
2019-11-25 Iniziato UBS Buy
2019-11-25 Iniziato Wells Fargo Outperform
Mostra tutto

Rapt Therapeutics Inc Borsa (RAPT) Ultime notizie

pulisher
May 28, 2025

RAPT Therapeutics Faces Nasdaq Delisting Notice - TipRanks

May 28, 2025
pulisher
May 26, 2025

What is HC Wainwright’s Forecast for RAPT Q2 Earnings? - Defense World

May 26, 2025
pulisher
May 25, 2025

UBS Group Cuts RAPT Therapeutics (NASDAQ:RAPT) Price Target to $1.00 - Defense World

May 25, 2025
pulisher
May 24, 2025

RAPT Therapeutics (NASDAQ:RAPT) Stock Rating Upgraded by HC Wainwright - Defense World

May 24, 2025
pulisher
May 23, 2025

D. E. Shaw & Co. Inc. Sells 278,173 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World

May 23, 2025
pulisher
May 22, 2025

RAPT Stock: HC Wainwright & Co. Announces New Price Target | RAP - GuruFocus

May 22, 2025
pulisher
May 22, 2025

UBS Adjusts Price Target for Rapt Therapeutics (RAPT) | RAPT Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

RAPT Analyst Update: UBS Adjusts Price Target to $1 | RAPT Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Rapt Therapeutics (RAPT) Receives Buy Rating with Promising Outl - GuruFocus

May 22, 2025
pulisher
May 22, 2025

UBS Adjusts Price Target for Rapt Therapeutics (RAPT) | RAPT Sto - GuruFocus

May 22, 2025
pulisher
May 22, 2025

Rapt Therapeutics (RAPT) Receives Buy Rating with Promising Outlook | RAPT Stock News - GuruFocus

May 22, 2025
pulisher
May 22, 2025

UBS cuts Rapt Therapeutics stock target to $1 from $2 By Investing.com - Investing.com UK

May 22, 2025
pulisher
May 19, 2025

Comerica Bank Purchases Shares of 58,040 RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World

May 19, 2025
pulisher
May 18, 2025

Dimensional Fund Advisors LP Sells 105,231 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World

May 18, 2025
pulisher
May 16, 2025

Rapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should Know - Yahoo Finance

May 16, 2025
pulisher
May 09, 2025

RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire

May 09, 2025
pulisher
May 09, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of “Hold” by Analysts - Defense World

May 09, 2025
pulisher
May 09, 2025

RAPT Therapeutics Reports Improved Q1 2025 Results - TipRanks

May 09, 2025
pulisher
May 08, 2025

RAPT Therapeutics Reports First Quarter 2025 Financial Results - GlobeNewswire

May 08, 2025
pulisher
May 08, 2025

RAPT Therapeutics, Inc. SEC 10-Q Report - TradingView

May 08, 2025
pulisher
May 05, 2025

RAPT Therapeutics Reports Third Quarter 2024 Financial Results - ADVFN

May 05, 2025
pulisher
May 05, 2025

RAPT Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 04, 2025

Renaissance Technologies LLC Has $584,000 Stock Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World

May 04, 2025
pulisher
May 03, 2025

JPMorgan Chase & Co. Raises Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT) - Defense World

May 03, 2025
pulisher
May 02, 2025

There is no way RAPT Therapeutics Inc (RAPT) can keep these numbers up - Sete News

May 02, 2025
pulisher
May 01, 2025

A stock that deserves closer examination: RAPT Therapeutics Inc (RAPT) - uspostnews.com

May 01, 2025
pulisher
May 01, 2025

Market Recap: RAPT Therapeutics Inc (RAPT)’s Positive Momentum, Closing at 0.93 - DWinneX

May 01, 2025
pulisher
May 01, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares Acquired by Geode Capital Management LLC - Defense World

May 01, 2025
pulisher
Apr 27, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 27, 2025
pulisher
Apr 24, 2025

RAPT Therapeutics Inc (RAPT) is a good investment, but the stock may be overvalued - uspostnews.com

Apr 24, 2025
pulisher
Apr 21, 2025

Stock Surge: RAPT Therapeutics Inc (RAPT) Closes at 0.79, Marking a -1.32 Increase/Decrease - DWinneX

Apr 21, 2025
pulisher
Apr 18, 2025

Is RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth? - Yahoo Finance

Apr 18, 2025
pulisher
Apr 18, 2025

RAPT stock touches 52-week low at $0.78 amid sharp annual decline - Investing.com Canada

Apr 18, 2025
pulisher
Apr 17, 2025

RAPT stock touches 52-week low at $0.78 amid sharp annual decline By Investing.com - Investing.com South Africa

Apr 17, 2025
pulisher
Apr 15, 2025

Rapt Therapeutics appoints Jessica Savage as VP, clinical development - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

RAPT Therapeutics (RAPT) Strengthens Leadership with New VP for Clinical Development | RAPT Stock News - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

RAPT Therapeutics Deepens Expertise in Allergic Diseases - GlobeNewswire

Apr 15, 2025
pulisher
Apr 15, 2025

Top Allergy Expert Joins RAPT to Accelerate Novel Food Allergy Treatment Pipeline - Stock Titan

Apr 15, 2025
pulisher
Apr 14, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Brokerages - Defense World

Apr 14, 2025
pulisher
Apr 13, 2025

40,218 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Bought by Sei Investments Co. - Defense World

Apr 13, 2025
pulisher
Mar 20, 2025

RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Consensus Recommendation of “Hold” from Analysts - Defense World

Mar 20, 2025
pulisher
Mar 19, 2025

Ultragenyx (RARE) Aligns With FDA on Phase III Neuro Study Plans - MSN

Mar 19, 2025
pulisher
Mar 13, 2025

Q1 EPS Forecast for RAPT Therapeutics Increased by Analyst - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Equities Analysts Set Expectations for RAPT FY2026 Earnings - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

RAPT Therapeutics (NASDAQ:RAPT) Given “Buy” Rating at HC Wainwright - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

H.C. Wainwright maintains $10 target on RAPT Therapeutics stock By Investing.com - Investing.com Canada

Mar 10, 2025
pulisher
Mar 10, 2025

RAPT Therapeutics: Strategic Licensing and Strong Cash Position Support Buy Rating Despite Financial Loss - TipRanks

Mar 10, 2025
pulisher
Mar 07, 2025

RAPT Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire

Mar 07, 2025
pulisher
Mar 07, 2025

Double Feature: RAPT Therapeutics Takes Center Stage at Major Healthcare Investment Forums - StockTitan

Mar 07, 2025
pulisher
Mar 07, 2025

Promising Developments and Strategic Trials Boost RAPT Therapeutics’ Buy Rating - TipRanks

Mar 07, 2025
pulisher
Mar 06, 2025

RAPT Therapeutics Focuses on RPT904 Development in 2025 - TipRanks

Mar 06, 2025

Rapt Therapeutics Inc Azioni (RAPT) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$1.08
price up icon 1.89%
$30.14
price down icon 3.74%
$573.26
price down icon 1.32%
$304.56
price up icon 3.98%
$4.50
price down icon 3.02%
$490.28
price down icon 19.01%
Capitalizzazione:     |  Volume (24 ore):